Veritas Genetics Inc.

Veritas Genetics Inc. provides advanced genetic testing services, focusing on whole exome and genome sequencing to deliver detailed insights into genetic information. Their solutions empower healthcare professionals and consumers with personalized health data. Founded in 2014 and headquartered in Danvers, US, Veritas Genetics Inc.

specializes in genetic testing services that encompass a range of diagnostics and preventive solutions. The company was founded by Mirza Cifric, who serves as the CEO. In November 2021, Veritas was acquired by PrivaPath Diagnostics Limited, marking a significant transition in its operational strategy. The company has engaged in a total of 6 funding deals, most recently securing USD 4.

60 mn in funding from investors including Alpha Square Group and MassVentures, totaling USD 4. 60 mn raised to date. Veritas specializes in advanced genetic testing services, focusing on whole exome and genome sequencing to provide comprehensive insights into individual genetic information. Their core offerings include preventive medicine solutions that assess risks for common diseases, non-invasive prenatal testing for chromosomal abnormalities, and diagnostic genomics that evaluate hereditary conditions such as cardiovascular diseases and cancers.

The company also provides a suite of personalized services, including myGenome, myGeneticRisk, and myHealthScore, which cater to different aspects of genetic healthcare management. Veritas serves a diverse clientele across multiple geographical markets, including the United Kingdom, Spain, Italy, Brazil, and several Latin American countries such as Colombia and Mexico, targeting both individual consumers and healthcare professionals who seek to enhance patient care through genetic insights. Veritas generates revenue through a structured transactional model that includes direct-to-consumer sales and partnerships with healthcare providers. Their offerings are typically provided as one-time genetic testing services, each accompanied by mandatory genetic counseling sessions that facilitate the interpretation of results and the development of actionable healthcare plans.

The firm focuses on a comprehensive pricing strategy that reflects the sophistication of its testing technologies and the expertise involved in analyzing genetic data. Their flagship products, such as myGenome and myPrenatal, are designed to deliver high clinical utility, ultimately enhancing the quality and longevity of life for users. The revenue model is built on the value of providing significant insights into genetics while ensuring that medical professionals guide the interpretation and application of test results. Veritas Genetics plans to leverage recent funding secured in November 2021 to support its product development and market expansion initiatives.

The company aims to enhance its product line with new genetic testing offerings and plans to penetrate additional markets, specifically targeting expansion into Europe and Latin America by 2023. This strategic approach is designed to align with their vision of making genetic insights more accessible to consumers globally.